Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.

Hildegund C J Ertl1

  • 1Wistar Institute, 3600 Spruce Street, Philadelphia, PA 19104, USA. ertl@wistar.upenn.edu

Current Opinion in Molecular Therapeutics
|February 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial.

The Lancet. Infectious diseases·2026
Same author

Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.

Nature communications·2025
Same author

Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated Cancer.

Vaccines·2024
Same author

Treatment with the PPARα agonist fenofibrate improves the efficacy of CD8<sup>+</sup> T cell therapy for melanoma.

Molecular therapy oncolytics·2023
Same author

Circumventing B Cell Responses to Allow for Redosing of Adeno-Associated Virus Vectors.

Human gene therapy·2023
Same author

Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression.

Drugs·2023
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Therion Biologics is developing a novel pox virus-based vaccine, ALVAC-CEA/B7.1, targeting carcinoembryonic antigen (CEA) for lung and colorectal cancer treatment. This promising cancer immunotherapy is currently in phase II clinical trials.

Area of Science:

  • Oncology
  • Immunotherapy
  • Vaccine Development

Background:

  • Carcinoembryonic antigen (CEA) is a tumor-associated antigen frequently expressed in lung and colorectal cancers.
  • Novel therapeutic strategies are needed to improve treatment outcomes for these prevalent malignancies.

Purpose of the Study:

  • To evaluate the safety and efficacy of ALVAC-CEA/B7.1 as a potential treatment for lung and colorectal cancer.
  • To assess the potential of targeting carcinoembryonic antigen (CEA) using a recombinant pox virus vaccine.

Main Methods:

  • ALVAC-CEA/B7.1 is a recombinant, pox virus-based vaccine developed by Therion Biologics and Aventis Pasteur.
  • The vaccine is designed to target cells expressing carcinoembryonic antigen (CEA).
  • The investigational therapy is currently undergoing phase II clinical trials.

Related Experiment Videos

Main Results:

  • Phase II clinical trials are ongoing to determine the efficacy and safety of ALVAC-CEA/B7.1.
  • The vaccine targets carcinoembryonic antigen (CEA) present on lung and colorectal tumor cells.

Conclusions:

  • ALVAC-CEA/B7.1 represents a novel approach in cancer immunotherapy for lung and colorectal cancers.
  • Further clinical evaluation is warranted to establish the therapeutic role of this CEA-targeting vaccine.